Ekso Bionics : Investor Presentation

Investor Presentation

December 2023

Copyright 2023. All rights reserved.

Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and expectations of management with respect to the Company's industry, growth and strategy, including the Company's focus on securing more multi-unit orders with large network operators and its ability to obtain sustainable, long-term growth, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the expected benefits of the acquisition of HMC, (v) number or percentage

of patients or workers that could potentially benefit from the Company's products, (vi) potential technological and operational improvements and timing, including with products such as Nomad and (vii) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv), (v) or (vi) above. Forward-looking statements can be identified by words such as "expect," "continue," "anticipate," "estimate," "believe," "plan," "projection," "grow," "potential," "future," "can," "develop," "proposition," "position," "expand" or words of similar meaning.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or

enhance the Company's technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad

market acceptance of the Company's products, the failure of the Company's sales and marketing efforts or of partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company's supply chain, the Company's ability to successfully integrate the HMC business and its personnel and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and

described in more detail in the Company's public filings with the Securities and Exchange Commission ("SEC"). You should carefully read the Cautionary Note Regarding Forward-Looking

Statements and the factors described in the "Risk Factors" section of the Company's public filings with the SEC to better understand the risks and uncertainties inherent in the Company. The Company does not undertake to update these forward-looking statements, except as required by law.

This presentation includes a discussion of cash flow, which is a financial measure that is not calculated in accordance with GAAP. For more information regarding cash flow, please see slide 20.

History

Business Segments in Wearable Exoskeletons

Enterprise

Elevating the standard of care for Neurorehabilitation for stroke, brain injury (ABI), MS, and SCI

1. Calabrò R.S., Antonino Naro, Margherita Russo, Placido Bramanti, Luigi Carioti, Tina Balletta, Antonio Buda, Alfredo Manuli, Serena Filoni and Alessia Bramanti. Shaping neuroplasticity by using powered exoskeletons in patients with stroke: a randomized clinical trial. Journal of NeuroEngineering and Rehabilitation (2018).
2. Swank C, Almutairi S, Wang-Price S, Gao F; Published in Topics in Stroke Rehabilitation. 2020 Oct;27(7):503-515. doi: 10.1080/10749357.2020.1728954
3. Nolan K, Karunakaran KK, Chervin K,MonfettMR, BapineeduRK, JaseyNN, Oh-Park M. Robotic exoskeleton gait training during acute stroke inpatient rehabilitation. Frontiers in Neurorobotics October 2020 (14).
4. Nolan KJ, et al. Utilization of Robotic Exoskeleton for Overground Walking in Acute and Chronic Stroke. FrontNeurorobot. 2021 Sep 1;15:689363.
5. Murray SA, Ha KH, Goldfarb M. An Assistive Controller for a Lower-Limb Exoskeleton for Rehabilitation after Stroke, and Preliminary Assessment Thereof. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:4083-6.doi: 10.1109/EMBC.2014.6944521.

Economic Value Proposition for Neuro-rehab Providers

Personal

Enabling independence in the SCI community

Global Presence

Largest mobile exoskeleton footprint globally with

450+ centers, 800+ devices deployed, 100s of millions of steps

Continuum of Care & Market Opportunity

Ekso can follow our patients through their rehabilitative process from hospital to home

Inpatient Rehab

Facility (IRF)

~1,200 centers1

~16% penetration